Ra Capital Management, L.P. - Nov 17, 2022 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Director, 10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
ACRV
Transactions as of
Nov 17, 2022
Transactions value $
$42,368,750
Form type
4
Date filed
11/21/2022, 03:31 PM
Previous filing
Nov 16, 2022
Next filing
Dec 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Conversion of derivative security +995K 995K Nov 17, 2022 See Footnotes F1, F2, F4
transaction ACRV Common Stock Purchase $42.4M +3.39M +340.75% $12.50 4.38M Nov 17, 2022 See Footnotes F2, F4
transaction ACRV Common Stock Conversion of derivative security +426K 426K Nov 17, 2022 See Footnotes F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Series B Preferred Stock Conversion of derivative security $0 -2.45M -100% $0.00* 0 Nov 17, 2022 Common Stock 995K See footnotes F1, F2, F4
transaction ACRV Series B Preferred Stock Conversion of derivative security $0 -1.05M -100% $0.00* 0 Nov 17, 2022 Common Stock 426K See footnotes F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 17, 2022 each share of Series B Preferred Stock (the "Preferred Stock") converted into Common Stock of the Issuer at a ratio of 1-for-2.466 upon closing of the initial public offering of the Issuer's common stock without payment of further consideration. The shares had no expiration date.
F2 These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3 These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").
F4 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Remarks:

Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.